e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

24.72 +0.54 (+2.23%)

Streaming Delayed Price Updated: 12:55 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >

ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗

January 01, 2026

Via Chartmill

Which stocks are moving after the closing bell on Tuesday? ↗

December 02, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗

November 24, 2025

Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones.

Via Stocktwits

Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 18, 2025

Via Benzinga

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

5 Analysts Have This To Say About Zymeworks ↗

October 24, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings) ↗

March 10, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

November 17, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 17, 2025

Via Benzinga

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

November 17, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays

November 17, 2025

U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones...

Via MarketMinute

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

November 17, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗

November 11, 2025

Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate.

Via Chartmill

Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗

November 06, 2025

Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data.

Via Chartmill

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 14, 2025

Via Benzinga

This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 14, 2025

Via Benzinga

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit ↗

September 02, 2025

Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251.

Via Benzinga

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗

September 02, 2025

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.

Via Stocktwits

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 22, 2025

Via Benzinga

Which stocks are moving after the closing bell on Friday? ↗

August 22, 2025

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge ↗

May 30, 2025

Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines.

Via Stocktwits

TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy ↗

May 21, 2025

The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development.

Via Stocktwits

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

Earnings Scheduled For March 5, 2025 ↗

March 05, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy